Paper Details

  1. Home
  2. Paper Details

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).

Author: AthanasiouStavros, Cambronero SantosJavier, ChappleChristopher R, DrakeMarcus J, EsenAdil, HerschornSender, HuangMoses, MacDiarmidScott, MitchesonDavid, SiddiquiEmad, StoelzelMatthias

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The BESIDE study showed that combined therapy of solifenacin and mirabegron improved efficacy over solifenacin monotherapy in overactive bladder (OAB) patients without exacerbating anticholinergic side effects. However, further research is needed to investigate a potential synergistic effect of this combination on the cardiovascular (CV) system.
Paper Details　
Original Abstract of the Article :
Label="AIMS/OBJECTIVES" NlmCategory="OBJECTIVE">In the BESIDE study, combination therapy (antimuscarinic [solifenacin] and &#946;<sub>3</sub> -adrenoceptor agonist [mirabegron]) improved efficacy over solifenacin monotherapy without exacerbating anticholinergic side effects in overactive bladder (OA...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485167/

データ提供：米国国立医学図書館（NLM）

Mirabegron: A Potential Oasis in the Desert of Overactive Bladder

Overactive bladder (OAB) is a common condition that can significantly impact quality of life, often creating a desert of discomfort and inconvenience. This research investigates the potential of mirabegron, a β3-adrenoceptor agonist, to improve the efficacy of solifenacin, an antimuscarinic drug, in treating OAB. The study explores the safety of this combination therapy, revealing its potential to improve bladder control without exacerbating anticholinergic side effects.

A New Oasis in the Desert of Bladder Control

This research offers a potential oasis in the desert of OAB. The study's findings suggest that mirabegron, when combined with solifenacin, may offer improved bladder control without increasing the risk of cardiovascular side effects.

Navigating the Desert of Bladder Control: A Guide for Management

This research highlights the potential benefits of mirabegron in managing OAB. The study's findings suggest that mirabegron, when combined with solifenacin, may provide a safe and effective approach to improving bladder control.

Dr. Camel's Conclusion

This research explores a potential oasis in the desert of OAB, revealing the potential of mirabegron to enhance the effectiveness of solifenacin while minimizing cardiovascular risks. The study provides a valuable roadmap for future research in this area, exploring the optimal use of this combination therapy for managing OAB.

Date :
  1. Date Completed 2018-07-16
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

28419650

DOI: Digital Object Identifier

PMC5485167

Related Literature

Article Analysis
・Side Effects of solifenacin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.